uniQure (NASDAQ:QURE) Stock Rating Upgraded by StockNews.com

uniQure (NASDAQ:QURE) was upgraded by research analysts at StockNews.com to a “sell” rating in a note issued to investors on Tuesday.

Several other equities research analysts have also weighed in on the company. Leerink Partners increased their target price on uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 11th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $24.00 price objective on shares of uniQure in a report on Tuesday, January 21st. The Goldman Sachs Group boosted their target price on shares of uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a research note on Thursday, December 12th. Raymond James upgraded shares of uniQure from an “outperform” rating to a “strong-buy” rating and raised their price target for the company from $20.00 to $52.00 in a research note on Tuesday, December 10th. Finally, Cantor Fitzgerald increased their price objective on uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $38.89.

uniQure Stock Up 6.7 %

NASDAQ:QURE opened at $13.34 on Tuesday. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The stock has a 50 day moving average of $14.18 and a 200-day moving average of $10.11. The firm has a market capitalization of $721.39 million, a PE ratio of -2.69 and a beta of 0.36. uniQure has a 52 week low of $3.73 and a 52 week high of $19.18.

Insiders Place Their Bets

In other uniQure news, CFO Christian Klemt sold 14,341 shares of uniQure stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $10.70, for a total transaction of $153,448.70. Following the transaction, the chief financial officer now directly owns 152,372 shares in the company, valued at approximately $1,630,380.40. The trade was a 8.60 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Matthew C. Kapusta sold 28,341 shares of the company’s stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total value of $291,628.89. Following the completion of the transaction, the chief executive officer now directly owns 651,454 shares in the company, valued at approximately $6,703,461.66. The trade was a 4.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 90,830 shares of company stock worth $961,401. 4.74% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. RTW Investments LP bought a new stake in uniQure in the 3rd quarter valued at $49,000. Atria Investments Inc acquired a new stake in uniQure during the third quarter worth about $53,000. Quarry LP acquired a new stake in uniQure during the third quarter worth about $58,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in uniQure during the third quarter valued at about $69,000. Finally, Twin Tree Management LP acquired a new position in uniQure in the 4th quarter valued at approximately $77,000. Institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.